IGF-1 LR3 Dosing Protocol

IGF-1 LR3 is a modified version of IGF-1 (insulin-like growth factor 1), one of the body's most powerful natural growth signals. It promotes muscle growth, supports recovery, and helps shuttle nutrients into cells. The "LR3" modification makes it roughly 3 times more potent than natural IGF-1 and extends its active duration from about 12–15 hours to 20–30 hours — meaning a single daily dose maintains elevated growth signaling around the clock.

What makes IGF-1 LR3 more potent is a structural change that prevents it from being captured and deactivated by binding proteins (called IGFBPs) that normally limit how much IGF-1 is available to work. The result: more of the molecule reaches its target receptors. Technically, IGF-1 LR3 is an 83-amino-acid peptide with two modifications to the native 70-amino-acid IGF-1 chain — an arginine substitution at position 3 and a 13-amino-acid extension at the front end.

IGF-1 LR3 has no formal human clinical development program. It was originally created as a laboratory reagent for cell-culture research and is now widely available through grey-market peptide suppliers. The closest clinical reference point is mecasermin (brand name Increlex), which is natural recombinant IGF-1 — not LR3 — that the FDA approved in 2005 for children with severe IGF-1 deficiency. Mecasermin's safety data is the best available guide to IGF-1 pathway risks, but it cannot be assumed equivalent to unsupervised IGF-1 LR3 use. IGF-1 LR3 is banned by WADA and all major sporting organizations.

This compound is not FDA-approved for any human therapeutic indication. All information on this page is for educational and research reference purposes only.

The table below shows the most commonly cited IGF-1 LR3 community dosing protocol. These are not clinical recommendations — no human trial has established optimal IGF-1 LR3 doses. Always start at the lowest dose to assess tolerance, especially for hypoglycemia risk.

**The #1 safety risk with IGF-1 LR3 is low blood sugar (hypoglycemia).** In the closest comparable clinical program, 42% of patients experienced hypoglycemia — making it by far the most common side effect. Always eat carbohydrates and protein when you inject, and keep fast-acting glucose (juice, glucose tablets) nearby. Other notable concerns include water retention, headaches, and long-term cancer risk from sustained growth-factor signaling. No formal human clinical trials exist specifically for IGF-1 LR3. The safety data below is drawn primarily from mecasermin (Increlex), the FDA-approved native IGF-1, studied in 71 pediatric subjects for an average of 3.9 years.

Hypoglycemia (most significant risk): In Increlex clinical trials, hypoglycemia was reported in 42% of participants. Symptoms include shakiness, sweating, dizziness, confusion, rapid heartbeat, and blurred vision. Severe episodes can be life-threatening. Always pair administration with carbohydrate and protein intake, and keep fast glucose available.

Water retention and joint effects: Edema and fluid-related effects were common in IGF-1 therapy datasets. Community protocols also report puffiness, mild swelling, and joint stiffness, often dose-dependent and reversible with dose reduction or cycle discontinuation.

Headaches: Headaches are commonly reported early. Increlex safety guidance includes intracranial hypertension monitoring. Persistent or severe headaches, especially with visual symptoms, require medical evaluation.

Injection site reactions: Lipohypertrophy and local irritation can occur. Rotate injection sites consistently.

Organ growth concerns (long-term): Increlex labeling notes rapid increases in renal and splenic length in some patients. Long-term supraphysiologic IGF-1 exposure carries theoretical hypertrophy risk in organ systems.

Cancer risk (theoretical/preclinical): IGF-1 signaling is mitogenic. In 2-year rat carcinogenicity studies with Increlex, increased tumor incidence occurred at high exposure. Elevated IGF-1 is associated with higher risk across some cancer epidemiology datasets. Preclinical IGF-1 LR3 studies have also reported increased tumor growth in tumor-bearing models.

Natural GH suppression: Exogenous IGF-1 may reduce endogenous GH through hypothalamic-pituitary feedback. This supports cycling and timing strategies that avoid sleep-proximal dosing.

Discontinuation rates: In the Increlex program, no subjects withdrew due to adverse reactions, but this does not directly establish comparable risk for unsupervised IGF-1 LR3 protocol contexts.

For a cross-class safety comparison, see the PepPal Peptide Side Effects Guide.

Important context for reading this table: IGF-1 LR3 itself has never been tested in a formal human clinical trial. The first six rows below are animal or cell-culture studies that established IGF-1 LR3's potency and biological effects. The last three rows come from human trials of mecasermin (Increlex) — which is native IGF-1, not the LR3 variant — and provide the best available window into IGF-1 pathway safety in humans. These mecasermin results inform our understanding of IGF-1 LR3 risks but are not direct evidence for this specific compound.

IGF-1 LR3 has broad preclinical use and strong mechanistic plausibility but no dedicated human clinical trial program. Most human safety context comes from native rhIGF-1 (mecasermin), which informs pathway-level risk but cannot be assumed equivalent to IGF-1 LR3 in unsupervised protocol settings. No active ClinicalTrials.gov records were identified for IGF-1 LR3 itself.

These three compounds target the same growth system (GH/IGF-1 axis) but work at different levels — and they're not interchangeable.

**Choose IGF-1 LR3 if** you want systemic growth-factor signaling with once-daily dosing. Its long half-life (20–30 hours) provides sustained activity, making it the most convenient IGF-1 variant for overall anabolic and recomposition support.

**Choose IGF-1 DES if** you want localized, intense growth signaling at specific muscle sites. DES is roughly 10x more potent at the receptor but works for only 20–30 minutes, so it requires multiple daily injections and is used for site-specific work rather than systemic effects.

**Choose HGH (Somatropin) if** you want the broadest hormonal support — not just IGF-1 effects but also fat metabolism, sleep quality, skin/hair recovery, and overall endocrine balance. HGH works upstream by stimulating your body's own IGF-1 production, so effects build over weeks rather than days. It's also the only FDA-approved compound in this comparison.

Reconstitution, injection timing, cycling strategy, and safety monitoring differ meaningfully across all three compounds.